cfDNA Isolation Using Silica-Coated Magnetic Microbeads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating cell-free DNA (cfDNA) from blood plasma face challenges in efficiently recovering small fragment cfDNA while minimizing the recovery of high molecular weight genomic DNA (gDNA) contaminants, which is crucial for accurate cancer diagnostics and non-invasive monitoring due to the low abundance and short fragment size of tumor-derived cfDNA.
Innovation Solution
A size-selective method using silica-coated magnetic microbeads with a binding buffer comprising guanidinium thiocyanate and Triton X-100, along with 2-propanol, to selectively bind and isolate cfDNA fragments of 50-400 bp, reducing the recovery of higher molecular weight gDNA, allowing for efficient enrichment of tumor-derived cfDNA in cancer diagnostics and fetal cfDNA in prenatal testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional DNA isolation methods are used, then total DNA is recovered, but small fragment cfDNA is not efficiently enriched and high molecular weight gDNA contamination remains
Solution Approach 1:
The patent changes the chemical parameters of the binding buffer by incorporating guanidinium thiocyanate (a chaotropic agent) and Triton X-100 (a non-ionic detergent) along with 2-propanol. This chemical parameter change enables selective binding of small fragment cfDNA (50-400 bp) to silica-coated magnetic microbeads while preventing binding of high molecular weight gDNA, thus resolving the contradiction between size selection precision and recovery yield
Solution Approach 2:
The patent introduces silica-coated magnetic microbeads as an intermediary substance that mediates the separation between cfDNA and gDNA. The microbeads selectively bind cfDNA fragments in the 50-400 bp range through the optimized binding buffer conditions, allowing precise size selection while maintaining high recovery of target cfDNA and excluding gDNA contamination
2Object-affected harmful factors
If plasma samples are processed to remove WBCs to prevent gDNA contamination, then gDNA contamination is reduced, but the process time and complexity increase
Solution Approach 1:
The patent extracts or removes the harmful gDNA contamination directly from the plasma sample through size-selective binding to magnetic microbeads, eliminating the need for complex WBC removal steps. The binding buffer conditions ensure that only small fragment cfDNA binds to the microbeads while gDNA remains in solution and can be easily removed, thus reducing gDNA contamination without increasing process complexity
Solution Approach 2:
The patent replaces the mechanical/cellular separation approach (removing WBCs through centrifugation and layering) with a chemical/biochemical approach using chaotropic agents and selective binding. This substitution simplifies the isolation process by directly targeting DNA fragments based on size and chemical properties rather than requiring complex cellular separation steps
3Measurement precision
If size selection is performed to enrich small fragment cfDNA, then tumor-derived cfDNA is enriched, but the isolation time increases
Solution Approach 1:
The patent performs preliminary action by optimizing the binding buffer composition before the actual binding step. The pre-formulated buffer containing guanidinium thiocyanate, Triton X-100, and 2-propanol creates ideal conditions for selective cfDNA binding from the start, enabling rapid enrichment of tumor-derived cfDNA without requiring multiple sequential steps or extended incubation times
Solution Approach 2:
The patent employs dynamic control of binding conditions by using magnetic microbeads that can be rapidly manipulated with magnetic fields. The binding, washing, and elution steps are dynamically controlled to optimize throughput, allowing efficient size selection and tumor cfDNA enrichment to be completed in a time-efficient manner
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables rapid and efficient isolation of high-quality cfDNA from small plasma samples, completing the process in under 2 hours, with high-resolution size selection, suitable for downstream applications like PCR and next-generation sequencing, enhancing the detection of rare mutations and minimizing gDNA contamination.
Implementation Method 1
an aqueous suspension of silica coated magnetic microbeads capable of binding DNA
Implementation Method 2
a binding buffer comprising a detergent and a chaotropic agent
Implementation Method 3
a binding buffer comprising a detergent and a chaotropic agent
Implementation Method 4
2-propanol, to form a binding mixture thereof
Implementation Method 5
silica coated magnetic microbeads capable of binding DNA
Data Source
AI summary
A method for isolating cell-free DNA from liquid body sample, comprising the following steps: a) Providing liquid body sample; b) Adding to said sample: a solid phase capable of binding DNA; a binding buffer comprising a detergent and a chaotropic agent; and 2-propanol, to form a binding mixture thereof; c) Washing the solid phase to remove unbound material; and d) Eluting bound cell-free DNA, wherein the majority of the eluted DNA is <400 bp.